Recombinant bivalent vaccine against foot-and-mouth disease virus serotype O/A infection in guinea pig

Acta Biochimica et Biophysica Sinica

Volumn 36, Issue 9, 2004, Pages 589-596

  Yi, Jian Zhong ^a   Liu, Ming Qiu ^a   Zhu, Cai Zhu ^b   Zhang, Qiang ^a   Sheng, Zu Tian ^c   Du, Qing Yun ^c   Yan, Wei Yao ^a   Zheng, Zhao Xin ^a  

^a FUDAN UNIVERSITY   (China)

^b State Key Laboratory of Veterinary Etiological Biology   (China)

^c Virus Res Inst Zhejiang Acad A   (China)

Author keywords

Bivalent vaccine; FMDV serotype A; FMDV serotype O; Foot and mouth disease; Guinea pig; VP1 protein

Indexed keywords

AMINO ACID; DNA FRAGMENT; FOOT AND MOUTH DISEASE VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; RECOMBINANT VACCINE; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; GENETIC CODE; GUINEA PIG; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; SEROTYPE; T LYMPHOCYTE ACTIVATION; TANDEM REPEAT; VIRUS INFECTION; VIRUS VECTOR; VIRUS VIRULENCE;

ANIMALIA; BOVINAE; CAVIA; CAVIA PORCELLUS; DNA VIRUSES; FOOT-AND-MOUTH DISEASE VIRUS; PROKARYOTA; SUS SCROFA; VECTORS;

EID: 10344254892     PISSN: 05829879     EISSN: None     Source Type: Journal    
DOI: 10.1093/abbs/36.9.589     Document Type: Article

References (33)

1. Matthews J. Foot-and-mouth disease outbreak. Vet Rec, 2001, 148(9): 282
2. Callis JJ, McKercher PD, Graves JH. Foot-and-mouth disease - a review. J Am Vet Med Assoc, 1968, 153(12): 1798-1802
3. Brownlie J. Strategic decisions to evaluate before implementing a vaccine programme in the face of a foot-and-mouth disease (FMD) outbreak. Vet Rec, 2001, 148(12): 358-360
4. Bachrach HL, Moore DM, McKercher PD, Polatnick J. Immune and antibody responses to an isolated capsid protein of foot-and-mouth disease virus. J Immunol, 1975, 115(6): 1636-1641
5. Grubman MJ, Morgan DO. Antigenic comparison of foot-and-mouth disease virus serotypes with monoclonal antibodies. Virus Res, 1986, 6(1): 33-43
6. Huang H, Yang Z, Xu Q, Sheng Z, Xie Y, Yan W, You Y et al. Recombinant fusion protein and DNA vaccines against foot and mouth disease virus infection in guinea pig and swine. Viral Immunol, 1999, 12(1): 1-8
7. Zheng ZX, Xu QX, Mao CQ, Zhao HX, Jin JP, You YJ, Yan WY et al. Biosynthetic peptide vaccine against foot-and-mouth disease virus. In: Talwar GP, Rao KVS, Chauhn VS eds. Recombinant and Synthetic Vaccines. New Delhi: Narosa Publishing House, 1994, 30-35
8. Haberman AM, Moller C, McCreedy D, Gerhard WU. A large degree of functional diversity exists among helper T cells specific for the same anti-genie site of influenza hemagglutinin. J Immunol, 1990, 145(9): 3087-3094
9. Zaghouani H, Krystal M, Kuzu H, Moran T, Shah H, Kuzu Y, Schulman J et al. Cells expressing an H chain Ig gene carrying a viral T cell epitope are lysed by specific cytotoxic T cells. J Immunol, 1992, 148(11): 3604-3609
10. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA et al. Designing CD4 immunoadhesins for AIDS therapy. Nature, 1989, 337(6207): 525-531
11. Bona C, Brumeanu TD, Zaghouani H. Immunogenicity of microbial peptides grafted in self immunoglobulin molecules. Cell Mol Biol, 1994, 40(Suppl1): 21-30
12. Zaghouani H, Anderson SA, Sperber KE, Daian C, Kennedy RC, Mayer L, Bona CA. Induction of antibodies to the human immunodeficiency virus type I by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein. Proc Natl Acad Sci USA, 1995, 92(2): 631-635
13. Li GJ, Yan WY, Xu QX, Sheng ZT, Zheng ZX. Study on the DNA vaccine against foot-and-mouth disease virus using the heavy chain constant region of swine IgG as the carrier for peptide epitopes. Chin J Biotech, 2001, 17(3): 322-324
14. Zhao K, Chen GH, Zhang ZY, Yan WY, Zheng ZX. Using swine self IgG H chain as a carrier to construct a recombinant vaccine against type O foot-and-mouth disease virus infection. Chin J Biotech, 2000, 16(6): 679-683
15. Esterhuysen JJ, Prehaud C, Thomson GR. A liquid-phase blocking ELISA for the detection of antibodies to rabies virus. J Virol Methods, 1995, 51(1): 31-42
16. Robiolo B, Grigera PR, Periolo OH, Seki C, Bianchi T, Maradei E, la Torre JL. Assessment of foot and mouth disease vaccine potency by liquid-phase blocking ELISA: A proposal for an alternative to the challenge procedure in Argentina. Vaccine, 1995, 13(14): 1346-1352
17. Mckercher PD, Moore DM, Morgan DO, Robertson BH, Callis JJ, Kleid DG, Shire SJ et al. Dose-response evaluation of a genetically engineering foot-and-mouth disease virus polypeptide immunogen in cattle. Am J Vet Res, 1985, 46(3): 587-590
18. Newton SE, Clarke BE, Appleyard G, Francis MJ, Carroll AR, Rowlands DJ, Skehel J, Brown F. Novel Antigen Presentation via Vaccinia. Morden Approaches to New Vaccines. New York: Cold Spring Harbor Laboratory, 1987
19. Barry MA, Johnston SA. Biological features of genetic immunization. Vaccine, 1997, 15(8): 788-791
20. Mulcahy G, Pullen LA, Gale C, di Marchi RD, Doel TR. Mouse protection test as a predictor of the protective capacity of synthetic foot-and-mouth disease vaccines. Vaccine, 1991, 9(1): 19-24
21. Clarke BE, Newton SE, Carroll AR, Francis MJ, Appleyard G, Syred AD, Highfield PE et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature, 1987, 330(6146): 381-484
22. Winther MD, Allen G, Bomford RH, Brown F. Bacterially expressed antigenic peptide from foot-and-mouth disease virus capsid elicits variable immunologic responses in animals. J Immunol, 1986, 136(5): 1835-1840
23. Rothel JS, Wood PR, Seow HF, Lightowlers MW. Urea/DTT solubilization of a recombinant Taenia ovis antigen, 45W, expressed as a GST fusion protein results in enhanced protective immune response to the 45W moiety. Vaccine, 1997, 15(5): 469-472
24. Burroughs JN, Rowlands DJ, Sangar DV, Talbot P, Brown F. Further evidence for multiple proteins in the foot-and-mouth disease virus particle. J Gen Virol, 1971, 13(1): 73-84
25. Broekhuijsen MP, Blom T, Kottenhagen M, Pouwels PH, Meloen RH, Barteling SJ, EngerValk BE. Synthesis of fusion proteins containing antigenic determinants of foot-and-mouth disease virus. Vaccine, 1986, 4(2): 119-124
26. Volpina OM, Surovoy AY, Zhmak MN, Kuprianova MA, Koroev DO, Chepurkin AV, Toloknov AS et al. A peptide construct containing B-cell and T-cell epitopes from the foot-and-mouth disease viral VP1 protein induces efficient antiviral protection. Vaccine, 1999, 17(6): 577-584
27. Barnett PV, Pullen L, Staple RF, Lee LJ, Butcher R, Parkinson D, Doel TR. A protective anti-peptide antibody against the immunodominant site of the A24 Cruzeiro strain of foot-and-mouth disease virus and its reactivity with other subtype viruses containing the same minimum binding sequence. J Gen Virol, 1996, 77(Pt5): 1011-1018
28. Francis MJ, Hastings GZ, Brown F, McDermed J, Lu YA, Tam JP. Immunological evaluation of the multiple antigen peptide (Map) system using the major immunogenic site of foot-and-mouth-disease virus. Immunology, 1991, 73(3): 249-254
29. Meloen RH, Langeveld JP, Schaaper WM, Slootstra JW. Synthetic peptide vaccines: Unexpected fulfillment of discarded hope? Biologicals, 2001. 29(3-4): 233-236
30. Wu Q, Moraes MP, Grubman MJ. Recombinant adenovirus co-expressing capsid proteins of two serotypes of foot-and-mouth disease virus (FMDV): In vitro characterization and induction of neutralizing anti-bodies against FMDV in swine. Virus Res, 2003, 93(2): 211-219
31. Carrillo C, Wigdorovitz A, Oliveros JC, Zamorano PI, Sadir AM, Gomez N, Salinas J et al. Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants. J Virol, 1998, 72(2): 1688-1690
32. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med, 1991, 174(6): 1483-1489
33. Zaghouani H, Steinman R, Nonacs R, Shah H, Gerhard W, Bona C. Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science, 1993, 259(5092): 224-227